Emerging Capital Partners

Emerging Capital Partners (ECP) is a leading private equity firm focused on investing across the African continent, with a significant strategic emphasis on the healthcare and life sciences sectors. The firm is widely recognized for its "buy-and-build" strategy, most notably exemplified by the creation of Kelix Bio, a pan-African biopharmaceutical platform designed to manufacture and distribute affordable specialty generic drugs. Through its investments, ECP has facilitated the consolidation of pharmaceutical manufacturing sites and the expansion of digital health platforms like Vezeeta to improve patient access in emerging markets. In 2024, ECP successfully exited its landmark investment in Kelix Bio through a sale to a consortium led by Mubadala Investment Company. The firm continues to manage a diverse portfolio aimed at institutionalizing operations and scaling businesses within the African healthcare ecosystem.